SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
HEP_26057_sm_SuppFig1a.tif1934KSupporting Information Figure 1a. Prognostic significance of elevated CRP levels (≥1 mg/dl) assessed at second independent time point. Prognostic significance of elevated CRP levels (≥1 mg/dl) assessed at second independent time point in patients at BCLC-stage B (a) and patients at BCLC-stage C (b) in the validation cohort.
HEP_26057_sm_SuppFig1b.tif1893KSupporting Information Figure 1b. Prognostic significance of elevated CRP levels (≥1 mg/dl) assessed at second independent time point. Prognostic significance of elevated CRP levels (≥1 mg/dl) assessed at second independent time point in patients at BCLC-stage B (a) and patients at BCLC-stage C (b) in the validation cohort.
HEP_26057_sm_SuppFig2.tif1070KSupporting Information Figure 2. Patient selection in the TIPS-cohort
HEP_26057_sm_SuppFig3.tif1711KSupporting Information Figure 3. Distribution of numeric CRP levels in patients with “CRP, non-associated with clinically evident infection (CEI)” and “CRP, associated with clinically evident infection (CEI)”
HEP_26057_sm_SuppFig4.tif2191KSupporting Information Figure 4. Prognostic significance of “CRP, non-associated with clinically evident infection (CEI)” and “CRP, associated with clinically evident infection (CEI)” in patients with HCC. Prognostic significance of normal, “CRP, associated with CEI” and “CRP, non-associated with CEI” was assessed in the training cohort (left) and the validation cohort (right) by the Kaplan-Meier method.
HEP_26057_sm_SuppInfo.doc21KSupporting Information
HEP_26057_sm_SuppTable.doc135KSupporting Information Table.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.